The recently updated EMA page lists questions that marketing-authorisation holders (MAHs) may have on post-authorisation safety studies (PASSs). It provides an overview of the European Medicines Agency’s position on issues that are typically addressed in discussions or meetings with MAHs in the post-authorisation phase. Revised topics are marked ‘New’ or ‘Rev.’ upon publication.
- What is a non-interventional imposed PASS? New July 2017
- Under which procedure should I submit my non-interventional imposed PASS? New July 2017
- What if the results of a non-interventional imposed PASS make a variation necessary? New July 2017
- How shall I present my non-interventional imposed PASS and in which format? New July 2017
- To whom should I submit my imposed non-interventional PASS? New July 2017
- How do I submit a joint PASS? New July 2017
- How will my non-interventional imposed PASS protocol be handled? New July 2017
- How will my imposed non-interventional PASS final study report be handled? New July 2017
- Scientific advice for safety studies Rev. May 2017
- How shall I implement the outcome of a non-interventional imposed PASS final study report procedure? New July 2017
- When should I register my studies in the EU PAS Register? New July 2017
- Are outcomes of non-interventional imposed PASS published? New July 2017
- What fee do I have to pay? New July 2017
- Who should I contact if I have questions regarding my submission? New July 2017
[Read More…]
Acknowledgements:
- Mark Heinemann, Principal Regulatory Specialist, Real World Evidence, inVentiv Health Clinical
- Mirela Tudor, Senior Regulatory Specialist, Real World Evidence, inVentiv Health Clinical